Abstract
Therapeutic antibodies play an important role in pharmacotherapy. The Asn297 residue of the Fc region is bound by an N-linked glycan, which plays an important role in pharmacodynamics and pharmacokinetics of therapeutic antibodies. In particular, terminal galactose, sialic acid and fucose are known to affect antibody-dependent cellular cytotoxicity （ADCC）, complement-dependent cytotoxicity （CDC） and liver uptake. N-glycans bring therapeutic antibody. On the other hand, the enzyme-linked immunosorbent assay （ELISA method） is mainly used to measure antibody drugs. It is impossible to detect the changes in sugar chains by ELISA method. Recent studies have been demonstrating that antibody drugs also undergo structural changes （biotransformation） in vivo. Novel analytical method using mass spectrometry technology is attracting attention. In this paper, we introduce the role of N-glycans in therapeutic antibodies and also our research.
